Disrupting tumour blood vessels

Nature Reviews Cancer

Volumn 5, Issue 6, 2005, Pages 423-435

  Tozer, Gillian M ^a   Kanthou, Chryso ^a   Baguley, Bruce C ^b  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

^b UNIVERSITY OF AUCKLAND   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 DIMETHYL 5 (2 OXO 1H INDOL 3 YLMETHYLENE) 3 PYRROLEPROPIONIC ACID; 4 (1 AMINOETHYL) N (4 PYRIDYL)CYCLOHEXANECARBOXAMIDE; 5,6 DIMETHYLXANTHENONE 4 ACETIC ACID; ANTINEOPLASTIC AGENT; ARSENIC TRIOXIDE; AS 1404; ASI 404; AURISTATIN PE; COLCHICINE; COMBRETASTATIN; COMBRETASTATIN A1 PHOSPHATE; COMBRETASTATIN A4; COMBRETASTATIN A4 PHOSPHATE; MITOFLAXONE; MX 116407; N [2 [(4 HYDROXYPHENYL)AMINO] 3 PYRIDINYL] 4 METHOXYBENZENESULFONAMIDE; N ACETYLCOLCHINOL PHOSPHATE; NOCODAZOLE; NPI 2358; PIPERAZINEDIONE; PRODRUG; SERINE 2 METHOXY 5 [2 (3,4,5 TRIMETHOXYPHENYL)VINYL]ANILIDE; SEROTONIN; UNCLASSIFIED DRUG; VANDETANIB; VASCULAR TARGETING AGENT; VATALANIB; VINBLASTINE; VINCRISTINE; XANTHONE 4 ACETIC ACID;

BLOOD FLOW; CELL DEATH; CLINICAL TRIAL; HUMAN; NONHUMAN; PRIORITY JOURNAL; REVIEW; TUMOR BLOOD FLOW; TUMOR CELL; TUMOR VASCULARIZATION;

ANGIOGENESIS INHIBITORS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; BIBENZYLS; CAPILLARY PERMEABILITY; CLINICAL TRIALS; ENDOTHELIAL CELLS; HUMANS; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; STILBENES; XANTHONES;

EID: 20344379950     PISSN: 1474175X     EISSN: None     Source Type: Journal    
DOI: 10.1038/nrc1628     Document Type: Review

References (165)

1. Boyland, E. & Boyland, M. E. Studies in tissue metabolism. IX. The action of colchicine and B. typhosus extract. Biochem. J. 31, 454-460 (1937).
2. Seed, L., Slaughter, D. P. & Limarzi, L. R. Effect of colchicine on human carcinoma. Surgery 7, 696-709 (1940).
3. Ludford, R. J. Factors determining the action of colchicine on tumour growth. Br. J. Cancer 2, 75-86 (1948).
4. Algire, G. H., Legallais, F. Y. & Anderson, B. F. Vascular reactions of normal and malignant tissues in vivo. VI. The role of hypotension in the action of components of podophyllotoxin on transplanted sarcomas. J. Natl Cancer Inst. 14, 879-887 (1954). One of a classic series of papers on the vascular reactions of tumours.
5. Baguley, B. C., Holdaway, K. M., Thomsen, L. L., Zhuang, L. & Zwi, L. J. Inhibition of growth of colon 38 adenocarcinoma by vinblastine and colchicine: evidence for a vascular mechanism. Eur. J. Cancer 27, 482-487 (1991).
6. Hill, S. A., Lonergan, S. J., Denekamp, J. & Chaplin, D. J. Vinca alkaloids: anti-vascular effects in a murine tumour. Eur. J. Cancer 9, 1320-1324 (1993).
7. Hill, S. A., Sampson, L. E. & Chaplin, D. J. Anti-vascular approaches to solid tumour therapy: evaluation of vinblastine and flavone acetic acid. Int. J. Cancer 83, 119-123 (1995).
8. Pettit, G. R., Cragg, G. M. & Singh, S. B. Antineoplastic agents, 122. Constituents of Combretum caffrum. J. Nat. Prod. 50, 386-391 (1987). Describes the isolation of the combretastatins from their natural source.
9. Lin, C. M. et al. Interactions of tubulin with potent natural and synthetic analogs of the antimitotic agent combretastatin: a structural-activity study. Mol. Pharmacol. 34, 200-208 (1988).
10. Pettit, G. R. et al. Antineoplastic agents 322. Synthesis of combretastatin A-4 prodrugs. Anticancer Drug Des. 10, 299-309 (1995). Describes the synthesis of CA-4-P, the more soluble prodrug of CA-4, allowing its use in in vivo model systems.
11. McGown, A. T. & Fox, B. W. Structural and biochemical comparison of the anti-mitotic agents colchicine, combretastatin A4 and amphethinile. Anticancer Drug Des. 3, 249-254 (1989).
12. Pettit, G. R. & Lippert III, J. W. Antineoplastic agents 429. Syntheses of the combretastatin A-1 and combretastatin B-1 prodrugs. Anticancer Drug Des. 15, 203-216 (2000).
13. Holwell, S. E. & Bibby, M. C. Activity of combretastatin A1 phosphate in murine models of liver metastasis. Br. J. Cancer 85 (Suppl. 1), 34 (2001).
14. Hill, S. A., Tozer, G. M. & Chaplin, D. J. Preclinical evaluation of the antitumour activity of the novel vascular targeting agent Oxi 4503. Anticancer Res. 22, 1453-1458 (2002).
15. Holwell, S. E. et al. Combretastatin A-1 phosphate a novel tubulin-binding agent with in vivo vascular effects in experimental tumours. Anticancer Res. 22, 707-711 (2002).
16. Hua, J. et al. Oxi4503, a novel vascular targeting agent; effects on blood flow and antitumor activity in comparison to combretastatin A-4 phosphate. Anticancer Res. 23, 1433-1440 (2003).
17. Aleksandrzak, K., McGown, A. T. & Hadfield, J. A. Antimitotic activity of diaryl compounds with structures resembling combretastatin A-4. Anticancer Drugs 9, 545-550 (1998).
18. Hatanaka, T. et al. Novel B-ring modified combretastatin analogues: syntheses and antineoplastic activity. Bioorg. Med. Chem. Lett. 8, 3371-3374 (1998).
19. Ohsumi, K. et al. Novel combretastatin analogues effective against murine solid tumors: design and structure-activity relationships. J. Med. Chem. 41, 3022-3032 (1998).
20. Pettit, G. R. et al. Antineoplastic agents. 379. Synthesis of phenstatin phosphate. J. Med Chem. 41, 1688-1695 (1998).
21. Lawrence, N. J., Rennison, D., Woo, M., McGown, A. T. & Hadfield, J. A. Antimitotic and cell growth inhibitory properties of combretastatin A-4-like ethers. Bioorg. Med. Chem. Lett. 11, 51-54 (2001).
22. Hadimani, M. B. et al. Synthesis, in vitro, and in vivo evaluation of phosphate ester derivatives of combretastatin A-4. Bioorg. Med. Chem. Lett. 13, 1505-1508 (2003).
23. Ljou, J. P. et al. Concise synthesis and structure-activity relationships of combretastatin A-4 analogues, 1-aroylindoles and 3-aroylindoles, as novel classes of potent antitubulin agents. J. Med. Chem. 47, 4247-4257 (2004).
24. Perez-Melero, C. et al. A new family of quinoline and quinoxaline analogues of combretastatins. Bioorg. Med. Chem. Lett. 14, 3771-3774 (2004).
25. Sun, L., Vasilevich, N. I., Fuselier, J. A., Hocart, S. J. & Coy, D. H. Examination of the 1,4-disubstituted azetidinone ring system as a template for combretastatin A-4 conformationally restricted analogue design. Bioorg. Med. Chem. Lett. 14, 2041-2046 (2004).
26. Prinz, H. Recent advances in the field of tubulin polymerization inhibitors. Expert Rev. Anticancer Ther. 2, 695-708 (2002).
27. Hori, K., Saito, S., Nihei, Y., Suzuki, M. & Sato, Y. Antitumor effects due to irreversible stoppage of tumor tissue blood flow: evaluation of a novel combretastatin A-4 derivative, AC7700. Jpn. J. Cancer Res. 90, 1026-1038 (1999).
28. Nihei, Y. et al. A novel combretastatin A-4 derivative, AC-7700, shows marked antitumor activity against advanced solid tumors and orthotopically transplanted tumors. Jpn. J. Cancer Res. 90, 1016-1025 (1999).
29. Hori, K., Saito, S., Sato, Y. & Kubota, K. Stoppage of blood flow in 3-methylcholanthrene-induced primary tumor due to a novel combretastatin A-4 derivative, AC7700, and its antitumor effect. Med. Sci. Monit. 7, 26-33 (2001).
30. Hori, K., Saito, S. & Kubota, K. A novel combretastatin A-4 derivative, AC7700, strongly stanches tumour blood flow and inhibits growth of tumours developing in various tissues and organs. Br. J. Cancer 86, 1604-1614 (2002).
31. 4 prodrug-induced disruption of tumour perfusion and energetic status. Br. J. Cancer 77, 1761-1767 (1998).
32. Dark, G. D. et al. Combretastatin A-4, an agent that displays potent and selective toxicity toward tumor vasculature. Cancer Res. 57, 1829-1834 (1997). The first solid evidence for the combretastatins having a potent and selective vascular-disrupting effect in solid tumours.
33. Horsman, M., Ehrnrooth, E., Ladekarl, M. & Overgaard, J. The effect of combretastatin A-4 disodium phosphate in a C3H mouse mammary carcinoma and a variety of murine spontaneous tumors. Int. J. Radiat. Oncol. Biol. Phys. 42, 895-898 (1998).
34. Maxwell, R. J., Nielsen, F. U., Breidahl, T., Stodkilde-Jorgensen, H. & Horsman, M. R. Effects of combretastatin on murine tumours monitored by 31P MRS, 1H MRS and 1H MRI. Int. J. Radiat. Oncol. Biol. Phys. 42, 891-894 (1998).
35. Chaplin, D. J., Pettit, G. R. & Hill, S. A. Anti-vascular approaches to solid tumour therapy: evaluation of combretastatin A4 phosphate. Anticancer Res. 19, 189-196 (1999).
36. Grosios, K., Holwell, S. E., McGown, A. T., Pettit, G. R. & Bibby, M. C. In vivo and in vitro evaluation of combretastatin A-4 and its sodium phosphate prodrug. Br. J. Cancer 81, 1318-1327 (1999).
37. Tozer, G. M. et al. Combretastatin A-4 phosphate as a tumor vascular-targeting agent: early effects in tumors and normal tissues. Cancer Res. 59, 1626-1634 (1999).
38. Pedley, R. B. et al. Eradication of colorectal xenografts by combined radioimmunotherapy and combretastatin a-4 3-O-phosphate. Cancer Res. 61, 4716-4722 (2001).
39. Lin, C. M., Ho, H. H., Pettit, G. R. & Hamel, E. Antimitotic natural products combretastatin A-4 and combretastatin A-2: studies on the mechanism of their inhibition of the binding of colchicine to tubulin. Biochemistry 28, 6984-6991 (1989).
40. Rustin, G. J. et al. Phase I clinical trial of weekly combretastatin A4 phosphate: clinical and pharmacokinetic results. J. Clin. Oncol. 21, 2815-2822 (2003).
41. Plowman, J. et al. Flavone acetic acid: a novel agent with preclinical antitumor activity against colon adenocarcinoma 38 in mice. Cancer Treat. Rep. 70, 631-635 (1986).
42. Smith, G. P., Calveley, S. B., Smith, M. J. & Baguley, B. C. Flavone acetic acid (NSC 347512) induces haemorrhagic necrosis of mouse colon 26 and 38 tumours. Eur. J. Cancer Clin. Oncol. 23, 1209-1211 (1987).
43. Evelhoch, J. L. et al. Flavone acetic acid (NSC 347512)-induced modulation of murine tumor physiology monitored by in vivo nuclear magnetic resonance spectroscopy. Cancer Res. 48, 4749-4755 (1988).
44. Hill, S. A., Williams, K. B. & Denekamp, J. Vascular collapse after flavone acetic acid: a possible mechanism of its anti-tumour action. Eur. J. Cancer Clin. Oncol. 25, 1419-1424 (1989).
45. Zwi, L. J., Baguley, B. C., Gavin, J. B. & Wilson, W. R. Blood flow failure as a major determinant in the antitumor action of flavone acetic acid. J. Natl. Cancer Inst. 81, 1005-1013 (1989). References 44 and 45 provide an early introduction to the concept of vascular shutdown and how it might be measured.
46. Denekamp, J., Hill, S. A. & Hobson, B. Vascular occlusion and tumour cell death. Eur. J. Cancer Clin. Oncl. 19, 271-275 (1983).
47. Baguley, B. C. Antivascular therapy of cancer: DMXAA. Lancet Oncol. 4, 141-148 (2003).
48. Jameson, M. B. et al. Clinical aspects of a phase I trial of 5,6-dimethylxanthenone-4-acetic acid (DMXAA), a novel antivascular agent. Br. J. Cancer 88, 1844-1850 (2003). Report of the clinical trial of DMXAA that discusses some of the issues that have to be addressed when measuring tumour vascular effects in the clinic.
49. Tozer, G. M. et al. Mechanisms associated with tumor vascular shutdown induced by combretastatin A-4 phosphate: intravital microscopy and measurement of vascular permeability. Cancer Res. 61, 6413-6422 (2001). Detailed study of mechanisms of action of CA-4-P at the physiological level.
50. Zwi, L. J., Baguley, B. C., Gavin, J. B. & Wilson, W. R. Correlation between immune and vascular activities of xanthenone acetic acid antitumor agents. Oncol. Res. 6, 79-85 (1994).
51. Galbraith, S. M. et al. Effects of combretastatin A4 phosphate on endothelial cell morphology in vitro and relationship to tumour vascular targeting activity in vivo. Anticancer Res. 21, 93-102 (2001).
52. Kanthou, C. & Tozer, G. M. The tumor vascular targeting agent combretastatin A-4-phosphate induces reorganization of the actin cytoskeleton and early membrane blebbing in human endothelial cells. Blood 99, 2060-2069 (2002). Study of the cell-signalling events in endothelial cells in vitro, which are initiated by the effects of CA-4-P on the tubulin cytoskeleton and lead to functional changes in terms of monolayer permeability and assembly of junctional proteins.
53. Tozer, G. M., Kanthou, C., Parkins, C. S. & Hill, S. A. The biology of the combretastatins as tumour vascular targeting agents. Int. J. Exp. Pathol. 83, 21-38 (2002).
54. Tozer, G. M. et al. Intravital imaging of tumour vascular networks using multi-photon fluorescence microscopy. Adv. Drug Deliv. Rev. 57, 135-152 (2005).
55. Zhao, L., Ching, L. M., Kestell, P., Kelland, L. R. & Baguley, B. C. Mechanisms of tumor vascular shutdown induced by 5,6-dimethylxanthenone-4-acetic acid (DMXAA): Increased tumor vascular permeability. Int. J. Cancer (in the press).
56. Milosevic, M. F., Fyles, A. W. & Hill, R. P. The relationship between elevated interstitial fluid pressure and blood flow in tumors: a bioengineering analysis. Int. J. Radiat. Oncol. Biol. Phys. 43, 1111-1123 (1999). An instructive analysis of the role of interstitial fluid pressure in the control of tumour blood flow.
57. Blakey, D. C. et al. Antitumor activity of the novel vascular targeting agent ZD6126 in a panel of tumor models. Clin. Cancer Res. 8, 1974-1983 (2002).
58. Hori, K. & Saito, S. Microvascular mechanisms by which the combretastatin A-4 derivative AC7700 (AVE8062) induces tumour blood flow stasis. Br. J. Cancer 89, 1334-1344 (2003).
59. Hori, K. & Saito, S. Induction of tumour blood flow stasis and necrosis: a new function for epinephrine similar to that of combretastatin A-4 derivative AVE8062 (AC7700). Br. J. Cancer 90, 549-553 (2004).
60. Less, J. R., Skalak, T. C., Sevick, E. M. & Jain, R. K. Microvascular architecture in a mammary carcinoma: branching patterns and vessel dimensions. Cancer Res. 51, 265-273 (1991).
61. Lominadze, D. & Mchedlishvili, G. Red blood cell behavior at low flow rate in microvessels. Microvasc. Res. 58, 187-189 (1999).
62. Dudek, S. M. & Garcia, J. G. Cytoskeletal regulation of pulmonary vascular permeability. J. Appl. Physiol. 91, 1487-1500 (2001).
63. Dejana, E., Spagnuolo, R. & Bazzoni, G. Interendothelial junctions and their role in the control of angiogenesis, vascular permeability and leukocyte transmigration. Thromb. Haemost. 86, 308-315 (2001).
64. Dvorak, H. F., Nagy, J. A., Dvorak, J. T. & Dvorak, A. M. Identification and characerization of the blood vessels of solid tumors that are leaky to circulating macromolecules. Am. J. Pathol. 133, 95-109 (1988).
65. Lum, H. & Malik, A. B. Mechanisms of increased endothelial permeability. Can. J. Physiol. Pharmacol. 74, 787-800 (1996).
66. Bates, D. O. & Harper, S. J. Regulation of vascular permeability by vascular endothelial growth factors. Vascul. Pharmacol. 39, 225-237 (2002).
67. Su, M. Y. et al. Pharmacokinetic changes induced by vasomodulators in kidneys, livers, muscles, and implanted tumors in rats as measured by dynamic Gd-DTPA-enhanced MRI. Magn. Reson. Med. 36, 868-877 (1996).
68. Johansson, M., Henriksson, R., Bergenheim, A. T. & Koskinen, L. O. Interleukin-2 and histamine in combination inhibit tumour growth and angiogenesis in malignant glioma. Br. J. Cancer 83, 826-832 (2000).
69. Wojciak-Stothard, B. & Ridley, A. J. Rho GTPases and the regulation of endothelial permeability. Vascul. Pharmacol. 39, 187-199 (2002).
70. Garcia, J. G., Davis, H. W. & Patterson, C. E. Regulation of endothelial cell gap formation and barrier dysfunction: role of myosin light chain phosphorylation. J. Cell Physiol. 163, 510-522 (1995).
71. Amano, M. et al. Phosphorylation and activation of myosin by Rho-associated kinase (Rho-kinase). J. Biol. Chem. 271, 20246-20249 (1996).
72. Verin, A. D. et al. Microtubule disassembly increases endothelial cell barrier dysfunction: role of MLC phosphorylation. Am. J. Physiol. Lung Cell Mol. Physiol. 281, L565-L574 (2001).
73. Ye, L. H. et al. Myosin light-chain kinase of smooth muscle stimulates myosin ATPase activity without phosphorylating myosin light chain. Proc. Natl Acad Sci. USA 96, 6666-6671 (1999).
74. Brooks, A. C. et al. The vascular targeting agent combretastatin A-4-phosphate induces neutrophil recruitment to endothelial cells in vitro. Anticancer Res. 23, 3199-3206 (2003).
75. Parkins, C. S., Holder, A. J., Hill, S. A., Chaplin, D. J. & Tozer, G. M. Determinants of anti-vascular action by combretastatin A-4 phosphate: role of nitric oxide. Br. J. Cancer 83, 811-816 (2000).
76. Korbelik, M. & Cecic, I. Contribution of myeloid and lymphoid host cells to the curative outcome of mouse sarcoma treatment by photodynamic therapy. Cancer Lett. 137, 91-98 (1999).
77. Prise, V. E., Honess, D. J., Stratford, M. R. L., Wilson, J. & Tozer, G. M. The vascular response of tumor and normal tissues in the rat to the vascular targeting agent, combretastatin A-4-phosphate, at clinically relevant doses. Int. J. Oncol. 21, 717-726 (2002).
78. Nihei, Y. et al. Evaluation of antivascular and antimitotic effects of tubulin binding agents in solid tumor therapy. Jpn. J. Cancer Res. 90, 1387-1396 (1999).
79. Baguley, B. C., Zhuang, L. & Kestell, P. Increased plasma serotonin following treatment with flavone-8-acetic acid, 5,6-dimethylxanthenone-4-acetic acid, vinblastine, and colchicine: relation to vascular effects. Oncol. Res. 9, 55-60 (1997).
80. Alexander, J. S., Hechtman, H. B. & Shepro, D. Serotonin induced actin polymerization and association with cytoskeletal elements in cultured bovine aortic endothelium. Biochem. Biophys. Res. Commun. 143, 152-158 (1987).
81. Lash, C. J. et al. Enhancement of the anti-tumour effects of the antivascular agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA) by combination with 5-hydroxytryptamine and bioreductive drugs. Br. J. Cancer 78, 439-445 (1998).
82. Ahmed, B. et al. Vascular targeting effect of combretastatin A-4 phosphate dominates the inherent angiogenesis inhibitory activity. Int. J. Cancer 105, 20-25 (2003).
83. Iyer, S. et al. Induction of apoptosis in proliferating human endothelial cells by the tumor-specific antiangiogenesis agent combretastatin A-4. Cancer Res. 58, 4510-4514 (1998).
84. Kanthou, C. et al. The tubulin-binding agent combretastatin A-4-phosphate arrests endothelial cells in mitosis and induces mitotic cell death. Am. J. Pathol. 165, 1401-1411 (2004).
85. Hill, S. A., Chaplin, D. J., Lewis, G. & Tozer, G. M. Schedule dependence of combretastatin A4 phosphate in transplanted and spontaneous tumour models. Int. J. Cancer 102, 70-74 (2002).
86. Ching, L. M. et al. Induction of endothelial cell apoptosis by the antivascular agent 5,6-Dimethylxanthenone-4-acetic acid. Br. J. Cancer 86, 1937-1942 (2002).
87. Sheng, Y. et al. Combretastatin family member OXI4503 induces tumor vascular collapse through the induction of endothelial apoptosis. Int. J. Cancer 111, 604-610 (2004).
88. Kirwan, I. G. et al. Comparative preclinical pharmacokinetic and metabolic studies of the combretastatin prodrugs combretastatin A4 phosphate and A1 phosphate. Clin. Cancer Res. 10, 1446-1453 (2004).
89. Cao, Z., Baguley, B. C. & Ching, L. M. Interteron-inducible protein 10 induction and inhibition of angiogenesis in vivo by the antitumor agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA). Cancer Res. 61, 1517-1521 (2001).
90. Zhao, L., Ching, L. M., Kestell, P. & Baguley, B. C. Improvement of the antitumor activity of intraperitoneally and orally administered 5,6-dimethylxanthenone-4-acetic acid by optimal scheduling. Clin. Cancer Res. 9, 6545-6550 (2003).
91. Hendrix, M. J. et al. Expression and functional significance of VE-cadherin in aggressive human melanoma cells: role in vasculogenic mimicry. Proc. Natl Acad. Sci. USA 98, 8018-8023 (2001).
92. Zhao, L. S., Edgar, E., Marshall, L., Kelland, L. & Baguley, B. C. Inhibition of vasculogenic mimicry in melanoma by the antivascular drug 5,6-dimethylxanthenone-4-acetic acid (DMXAA). Eur. J. Cancer Suppl. 2(8), 47 (2004).
93. Ching, L. M. et al. Induction of intratumoral tumor necrosis factor (TNF) synthesis and hemorrhagic necrosis by 5,6-dimethylxanthenone-4-acetic acid (DMXAA) in TNF knockout mice. Cancer Res. 59, 3304-3307 (1999). Gives an introduction to the role of cytokines in the action of DMXAA.
94. Wang, L. C. et al. Induction of tumour necrosis factor and interferon-γ in cultured murine splenocytes by the antivascular agent DMXAA and its metabolites. Biochem. Pharmacol. 67, 937-945 (2004).
95. Kallinowski, F., Schaefer, C., Tyler, G. & Vaupel, P. In vivo targets of recombinant human tumour necrosis factor-α: blood flow, oxygen consumption and growth of isotransplanted rat tumours. Br. J. Cancer 60, 555-560 (1989).
96. Murata, R., Overgaard, J. & Horsman, M. R. Comparative effects of combretastatin A-4 disodium phosphate and 5,6-dimethylxanthenone-4-acetic acid on blood perfusion in a murine tumour and normal tissues. Int. J. Radiat. Biol. 77, 195-204 (2001).
97. Denekamp, J. & Hobson, B. Endothelial cell proliferation in experimental tumours. Br. J. Cancer 46, 711-720 (1982). One of a series of papers by this author setting out the principles and potential for therapeutic targeting of the tumour vasculature, which was influential in stimulating research in this field.
98. Eberhard, A. et al. Heterogeneity of angiogenesis and blood vessel maturation in human tumors: implications for antiangiogenic tumor therapies. Cancer Res. 60, 1388-1393 (2000).
99. Park, J. H. et al. Hypoxia/aglycemia increases endothelial permeability: role of second messengers and cytoskeleton. Am. J. Physiol. 277, C1066-C1074 (1999).
100. + influx and endothelial permeability. Am. J. Physiol. Lung Cell Mol. Physiol. 287, L1303-L1313 (2004).
101. Michel, C. C. & Curry, F. E. Microvascular permeability. Physiol. Rev. 79, 703-761 (1999). An excellent comprehensive review of microvascular permeability from the molecular to the physiological level.
102. + signaling in the regulation of endothelial permeability. Vascul. Pharmacol. 39, 173-185 (2002).
103. Beauregard, D. A., Hill, S. A., Chaplin, D. J. & Brindle, K. M. The susceptibility of tumors to the antivascular drug combretastatin A4 phosphate correlates with vascular permeability. Cancer Res. 61, 6811-6815, (2001).
104. Otani, M. et al. TZT-1027, an antimicrotubule agent attacks tumor vasculature and induces tumor cell death. Japn. J. Cancer Res. 91, 837-844 (2000).
105. Lew, Y. S., Brown, S. L., Griffin, R. J., Song, C. W. & Kim, J. H. Arsenic trioxide causes selective necrosis in solid murine tumors by vascular shutdown. Cancer Res. 59, 6033-6037 (1999).
106. Davis, P. D. et al. ZD6126: a novel vascular-targeting agent that causes destruction of tumor vasculature. Cancer Res. 62, 7247-7253 (2002).
107. Segreti, J. A. et al. Tumor selective antivascular effects of the novel antimitotic compound ABT-751: an in vivo rat regional hemodynamic study. Cancer Chemother. Pharmacol. 54, 273-281 (2004).
108. Kasibhatla, S. et al. Discovery and mechanism of action of a novel series of apoptosis inducers with potential vascular targeting activity. Mol. Cancer Ther. 3, 1365-1374 (2004).
109. Corada, M. et al. A monoclonal antibody to vascular endothelial-cadherin inhibits tumor angiogenesis without side effects on endothelial permeability. Blood 100, 905-911 (2002).
110. Blaschuk, O. W. & Rowlands, T. M. Cadherins as modulators of angiogenesis and the structural integrity of blood vessels. Cancer Metastasis Rev. 19, 1-5 (2000).
111. Abramovitch, R., Dafni, H., Smouha, E., Benjamin, L. E. & Neeman, M. In vivo prediction of vascular susceptibility to vascular susceptibility endothelial growth factor withdrawal: magnetic resonance imaging of C6 rat glioma in nude mice. Cancer Res. 59, 5012-5016 (1999).
112. Ashrafpour, H. et al. Vasodilator effect and mechanism of action of vascular endothelial growth factor in skin vasculature. Am. J. Physiol. Heart. Circ. Physiol. 286, H946-H954 (2004).
113. Inai, T. et al. Inhibition of vascular endothelial growth factor (VEGF) signaling in cancer causes loss of endothelial fenestrations, regression of tumor vessels, and appearance of basement membrane ghosts. Am. J. Pathol. 165, 35-52 (2004).
114. Thorpe, P. E. Vascular targeting agents as cancer therapeutics. Clin. Cancer Res. 10, 415-427 (2004).
115. Dowlati, A. et al. A phase I pharmacokinetic and translational study of the novel vascular targeting agent combretastatin a-4 phosphate on a single-dose intravenous schedule in patients with advanced cancer. Cancer Res. 62, 3408-3416 (2002).
116. Gadgeel, S. M., LoRusso, P. M., Wozniak, A. J. & Wheeler, C. A dose-escalation study of the novel vascular-targeting agent, ZD6126, in patients with solid tumors. in Proc. Am. Soc. Clin. Oncol. 24, 438 (2002).
117. Galbraith, S. M. et al. Effects of 5,6-dimethylxanthenone-4-acetic acid on human tumor microcirculation assessed by dynamic contrast-enhanced magnetic resonance imaging. J. Clin. Oncol. 20, 3826-3840 (2002).
118. Anderson, H. L. et al. Assessment of pharmacodynamic vascular response in a phase I trial of combretastatin A4 phosphate. J. Clin. Oncol. 21, 2823-2830 (2003).
119. Galbraith, S. M. et al. Combretastatin A4 phosphate has tumor antivascular activity in rat and man as demonstrated by dynamic magnetic resonance imaging. J. Clin. Oncol. 21, 2831-2842 (2003). Report of the magnetic-resonance-imaging studies in the UK-based Phase I and II clinical trial of CA-4-P. This report shows that the pattern of vascular effects observed in humans is very similar to that predicted from animal studies.
120. Stevenson, J. P. et al. Phase I trial of the antivascular agent combretastatin A4 phosphate on a 5-day schedule to patients with cancer: magnetic resonance imaging evidence for altered tumor blood flow. J. Clin. Oncol. 21, 4428-4438 (2003).
121. Tolcher, A. W. et al. Phase I, pharmacokinetic, and DCE-MRI correlative study of AVE8062A, an antivascular combretastatin analogue, administered weekly for 3 weeks every 28 days. in Proc. Am. Soc. Clin. Oncol. 22, 834 (2003).
122. Evelhoch, J. L. et al. Magnetic resonance imaging measurements of the response of murine and human tumors to the vascular-targeting agent ZD6126. Clin. Cancer Res. 10, 3650-3657 (2004).
123. Young, S. L. & Chaplin, D. J. Combretastatin A4 phosphate: background and current clinical status. Expert Opin. Investig. Drugs 13, 1171-1182 (2004).
124. Steel, G. G. & Peckham, M. J. Exploitable mechanisms in combined radiotherapy-chemotherapy: the concept of additivity. Int. J. Radiat. Oncol. Biol. Phys. 5, 85-91 (1979).
125. Siemann, D. W. Vascular targeting agents. Horizons in Cancer Therapeutics: from Bench to Bedside 3, 4-15 (2002).
126. Cooney, M. M. et al. Cardiovascular safety profile of combretastatin a4 phosphate in a single-dose phase I study in patients with advanced cancer. Clin. Cancer Res. 10, 96-100 (2004).
127. Rustin, G. J. et al. 5,6-dimethylxanthenone-4-acetic acid (DMXAA), a novel antivascular agent: phase I clinical and pharmacokinetic study. Br. J. Cancer 88, 1160-1167 (2003).
128. Li, L., Rojiani, A. & Siemann, D. Targeting the tumor vasculature with combretastatin A-4 disodium phosphate: effects on radiation therapy. Int. J. Radiat. Oncol. Biol. Phys. 42, 899-903 (1998).
129. Wilson, W. R., Li, A. E., Cowan, D. S. & Siim, B. G. Enhancement of tumor radiation response by the antivascular agent 5,6-dimethylxanthenone-4- acetic acid. Int. J. Radiat. Oncol. Biol. Phys. 42, 905-908 (1998).
130. Horsman, M. R. et al. Combretastatins: novel vascular targeting drugs for improving anti-cancer therapy. Combretastatins and conventional therapy. Adv. Exp. Med. Biol. 476, 311-323 (2000).
131. Landuyt, W. et al. In vivo antitumor effect of vascular targeting combined with either ionizing radiation or antiangiogenesis treatment. Int. J. Radiat. Oncol. Biol. Phys. 49, 443-450 (2001).
132. Murata, R., Siemann, D. W., Overgaard, J. & Horsman, M. R. Improved tumor response by combining radiation and the vascular-damaging drug 5,6-dimethylxanthenone-4-acetic acid. Radiat. Res. 156, 503-509 (2001).
133. Murata, R., Siemann, D. W., Overgaard, J. & Horsman, H. R. Interaction between combretastatin A-4 disodium phosphate and radiation in murine tumors. Radiother. Oncol. 60, 155-161 (2001).
134. Siemann, D. W. & Rojiani, A. M. Enhancement of radiation therapy by the novel vascular targeting agent ZD6126. Int. J. Radiat. Oncol. Biol. Phys. 53, 164-171 (2002).
135. Siemann, D. W., Mercer, E., Lepler, S. & Rojiani, A. M. Vascular targeting agents enhance chemotherapeutic agent activities in solid tumor therapy. Int. J. Cancer 99, 1-6 (2002).
136. Bilenker, J. H. et al. Phase I trial of combretastatin a-4 phosphate with carboplatin. Clin. Cancer Res. 11, 1527-1533 (2005).
137. Jain, R. K. Delivery of molecular medicine to solid tumors. Science 271, 1079-1080 (1996).
138. Pedley, R. B. et al. Enhancement of antibody-directed enzyme prodrug therapy in colorectal xenografts by an antivascular agent. Cancer Res. 59, 3998-4003 (1999).
139. Pedley, R. B. et al. Synergy between vascular targeting agents and antibody-directed therapy. Int. J. Radiat. Oncol. Biol. Phys. 54, 1524-1531 (2002).
140. Grosios, K., Loadman, P. M., Swaine, D. J., Pettit, G. R. & Bibby M. C. Combination chemotherapy with combretastatin A-4 phosphate and 5-fluorouracil in an experimental murine colon adenocarcinoma. Anticancer Res. 20, 229-234 (2000).
141. Garcia-Barros, M. et al. Tumor response to radiotherapy regulated by endothelial cell apoptosis. Science 300, 1155-1159 (2003).
142. Wachsberger, P., Burd, R. & Dicker, A. P. Tumor response to ionizing radiation combined with antiangiogenesis or vascular targeting agents: exploring mechanisms of interaction. Clin. Cancer Res. 9, 1957-1971 (2003).
143. Siemann, D. W. & Horsman, M. R. Targeting the tumor vasculature: a strategy to improve radiation therapy. Expert. Rev. Anticancer Ther. 4, 321-327 (2004). An excellent review of the interaction of vascular-targeting agents with radiotherapy and the issues that need to be addressed.
144. El-Emir, E. et al. Tumour parameters affected by combretastatin A-4 phosphate therapy in a human colorectal xenograft model in nude mice. Eur. J. Cancer 41, 799-806 (2005).
145. Wachsberger, P. R. et al. Effect of the tumor vascular-damaging agent, ZD6126, on the radioresponse of U87 glioblastoma. Clin. Cancer. Res. 11, 835-842 (2005).
146. Boehle, A. S., Sipos, B., Kliche, U., Kalthoff, H. & Dohrmann, P. Combretastatin A-4 prodrug inhibits growth of human non-small cell lung cancer in a murine xenotransplant model. Ann. Thorac. Surg. 71, 1657-1665 (2001).
147. Siemann, D. W. & Shi, W. Efficacy of combined antiangiogenic and vascular disrupting agents in treatment of solid tumors. Int. J. Radiat. Oncol. Biol. Phys. 60, 1233-1240 (2004).
148. Siim, B. G., Denny, W. A. & Wilson, W. R. Nitro reduction as an electronic switch for bioreductive drug activation. Oncol. Res. 9, 357-369 (1997).
149. Theys, J. et al. Specific targeting of cytosine deaminase to solid tumors by engineered Clostridium acetobutylicum. Cancer Gene Ther. 8, 294-297 (2001).
150. Kobayashi, H. et al. Expression of α-smooth muscle actin in benign or malignant ovarian tumors. Gyn. Oncol. 48, 308-313 (1993).
151. Hashizume, H. et al. Openings between defective endothelial cells explain tumor vessel leakiness. Am. J. Pathol. 156, 1363-1380 (2000).
152. Paku, S. & Paweletz, N. First steps of tumor-related angiogenesis. Lab. Invest. 65, 334-346 (1991).
153. Baluk, P., Morikawa, S., Haskell, A., Mancuso, M. & McDonald, D. M. Abnormalities of basement membrane on blood vessels and endothelial sprouts in tumors. Am. J. Pathol. 163, 1801-1815 (2003).
154. Jain, R. K. Transport of molecules across tumor vasculature. Cancer Metastasis Rev. 6, 559-593 (1987).
155. Dvorak, H. F., Nagy, J. A. & Dvorak, A. M. Structure of solid tumors and their vasculature: implications for therapy with monoclonal antibodies. Cancer Cells 3, 77-85 (1991).
156. Boucher, Y., Baxter, L. T. & Jain, R. K. Interstitial pressure gradients in tissue-isolated and subcutaneous tumors: implications for therapy. Cancer Res. 50, 4478-4484 (1990).
157. Jain, R. K. & Ward-Hartley, K. Tumor blood flow-characterization, modifications and role in hyperthermia. IEEE Trans. on sonics & ultrasonics SU-31, 504-526 (1984).
158. Gillies, R. J., Schornack, P. A., Secomb, T. W. & Raghunand, N. Causes and effects of heterogenous perfusion in tumors. Neoplasia 1, 197-207 (1999).
159. Konerding, M. A. et al. Evidence for characteristic vascular patterns in solid tumours: quantitative studies using corrosion casts. Br. J. Cancer 80, 724-732 (1999).
160. Sevick, E. M. & Jain, R. K. Geometric resistance to blood flow in solid tumors ex vivo: effects of tumor size and perfusion pressure. Cancer Res. 49, 3506-3512 (1989).
161. Lominadze, D. & Mchedlishvili, G. Red blood cell behaviour at low flow rate in microvessels. Microvasc. Res. 58, 187-189 (1999).
162. Tozer, G. M., Lewis, S., Michalowski, A. & Aber, V. The relationship between regional variations in blood flow and histology in a transplanted rat fibrosarcoma. Br. J. Cancer 61, 250-257 (1990).
163. Mueller-Klieser, W., Vaupel, P. & Manz, R. Intracapillary oxyhemoglobin saturation of malignant tumors in humans. Int. J. Radiat. Oncol. Biol. Phys. 7, 1397-1404 (1981).
164. Vaupel, P. & Hockel, M. Blood supply, oxygenation status and metabolic micromilieu of breast cancers: characterization and therapeutic relevance. Int. J. Oncol. 17, 869-879 (2000).
165. Jain, R. K. & Baxter, L. T. Mechanisms of heterogeneous distribution of monoclonal antibodies and other macromolecules in tumors: significance of elevated interstitial pressure. Cancer Res. 48, 7022-7032 (1988). An excellent analysis of the role of interstitial pressure in the delivery of macromolecules to tumour tissue.